ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma
Open Access
- 1 May 2005
- journal article
- guideline
- Published by Elsevier in Annals of Oncology
- Vol. 16 (suppl_1) , i58-i59
- https://doi.org/10.1093/annonc/mdi820
Abstract
1Invited author and member of the task force, Oncology, Kantonsspital, CH-4101 Bruderholz/BL, Switzerland; 2Assigned task force member, Elisabeth Krankenhaus GmbH, Abt. Onkologie/Hämatologie, Röntgenstrasse 10, 45661 Recklinghausen, Germany; 3Assigned task force member, Division of Oncology, University Hospital, Rämistrasse 100, CH-8091 Zürich, SwitzerlandKeywords
This publication has 7 references indexed in Scilit:
- Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysisJournal of Clinical Oncology, 2004
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's LymphomasJournal of Clinical Oncology, 1999
- Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's LymphomaNew England Journal of Medicine, 1998
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]Blood, 1994
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993